US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Update to Faron’s Financial Calendar for 2024

Faron Pharmaceuticals Oy(“Faron” or “Company”)   Update to Faron’s Financial Calendar for 2024     Company announcement February 27, 2024 at 1:00 p.m. EST / 6:00 p.m. GMT / 8:00 p.m. EET TURKU, FINLAND / BOSTON, MA – February 27, 2024 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision immunotherapy, today announces an update to its financial reporting calendar for 2023, further to the to the announcement on December 22, 2023.   The

Faron at Proactive One2One Investor Forum

Faron Pharmaceuticals Ltd. ("Faron")   Faron to Present at the Proactive One2One Investor Forum   Press Release, January 24, 2022 at 02:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET)   TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron, will participate in the Proactive One2One Investor

Faron Announces Topline MATINS Biomarker Analysis

Faron Pharmaceuticals Ltd. (“Faron”) Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not Traditionally Benefited from Current Immunotherapy Treatments · Patients with low baseline levels of inflammatory cytokines in blood achieved significantly higher clinical benefit following treatment with bexmarilimab monotherapy · Low inflammatory biomarker profile is likely to predict bexmarilimab monotherapy clinical benefit   · Ignition of immune response, as indicated by increased levels of inflammatory cytokines following

Presentation of Updated MATINS Data at ESMO

Faron Pharmaceuticals Ltd. (“Faron”) Faron Announces Presentation of Updated MATINS Data at ESMO Showing Bexmarilimab Delivers Compelling Antitumour Activity Across Five Different Advanced Solid Tumors   ·Strongest disease control rate (DCR) observed in five different tumor types – cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients · Landmark analysis estimates overall survival at six months for DCR (partial response + stable disease rate) patients at 83% compared to 29% for non-DCR

Bexmarilimab granted key US patent

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab granted key US patent  Company announcement, 14 June 2021 at 9.00 AM (EEST)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761, with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021. Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab,

Bexmarilimab shows promising anti-tumour activity

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab monotherapy shows promising anti-tumour activity in multiple advanced solid tumours · Headline data reported from patients enrolled in completed Part I and ongoing Part II of MATINS study · Strongest disease control rate (DCR) of 31% seen in cutaneous melanoma, gastric cancer and cholangiocarcinoma patients · 100% six-month survival rate observed in DCR patients compared with 31.1 % for non-DCR patients · Equivalent prior treatment durations for DCR and non-DCR patients suggests DCR with bexmarilimab is

US rights to patent related to Traumakine

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron secures U.S. rights to patent related to Traumakine  Company announcement, 14 May 2021 at 9.00 AM (EEST)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033. The agreement clarifies Faron’s intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic

Financial statement January 1 to December 31 2020

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Financial statement release January 1 to December 31, 2020   ·Clevegen[®] (bexmarilimab) Phase I/II MATINS study has shown early clinical benefits in six hard-to-treat solid cancers with further combination studies planned · Intravenous interferon beta-1a Traumakine[®], for organ damage protection, now also investigated as potential COVID-19 treatment · Company’s balance sheet strengthened by successful share placings of €14 million and €15 million (post period) · Additional grants of €3.3 million and €4.6 million

Bexmarilimab (Clevegen) development update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab (Clevegen) development update · Significant survival benefit observed in patients responding to bexmarilimab treatment with risk of death reduced by 88% · Gastric cancer becomes sixth tumour cohort to show early signs of clinical efficacy · Data monitoring committee recommends dose escalation expansion in all six cohort types besides ongoing colorectal cancer Company announcement, 22 March 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON),

Notice of Full-Year Results and Annual Report

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Notice of Full-Year Results and Annual Report Company announcement, 25 February 2021 at 7.00 am GMT / 9.00 am EET TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, will publish its audited full-year results for the twelve months ended 31 December 2020 on Thursday 25 March 2021 at 7:00 GMT / 9:00 EET. The Annual Report 2020, including audited financial statements for the full year, will be published on the same day. A virtual briefing and Q&A session for

Update on TRAUMAKINE development

Faron Pharmaceuticals Oy (“Faron” or the “Company”) · U.S. Food and Drug Administration (FDA) approval of new HIBISCUS study protocol in patients with COVID-19 infection · Company seeking patent protection for the sequential use of IV interferon beta-1a and corticosteroids · Pipeline expansion into additional organ protection indications · CMC scale-up in progress Company announcement, 26 January 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces

Bexmarilimab (Clevegen) development update

· Cholangiocarcinoma becomes fifth tumour cohort to show early signs of efficacy · Increased bexmarilimab dosing schedule and high baseline regulatory T cell count associated with clinical benefit · High levels of soluble Clever-1 observed in MATINS patients · Soluble Clever-1 has the capacity to suppress T cell activation · Increased bexmarilimab dosing frequency to counter high levels of soluble Clever-1 underway  Company announcement, 20 January 2021 at 9.00 AM PM (EEST) Insider information  TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)

Presentations at ESMO Immuno-Oncology Virtual Congress build case for CLEVER-1 as a new immune checkpoint target

Data from ongoing PhI/II MATINS trial showcasedRole of myeloid cells in shaping the tumour microenvironment highlightedCompany announcement, 10 December 2020 at 9.00 AM (EET)TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that two presentations at the European Society of Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 will showcase data from the Company’s PhI/II MATINS study and explore the role of myeloid cells in shaping the tumour microenvironment (TME). ‘CLEVER-1 a new immune

Bexmarilimab (Clevegen) development update

· Accumulating MATINS data build foundation for further clinical development · Five patient cohorts in MATINS study Part II already fully recruited · Higher frequency of dosing introduced to investigate potential for enhanced clinical responses · Three new trials will study bexmarilimab treatment in neoadjuvant setting, in combination with PD(L)-1 checkpoint inhibitor and in haematological malignanciesCompany announcement, 23 November 2020 at 9.00 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company,

Traumakine Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”)· €2.5 million loan guarantee from Finnvera to further expand IV IFN beta-1a manufacturing process · AGC Biologics selected as new commercial scale manufacturer · COVID-19 trials continue to investigate Traumakine treatment Company announcement, 18 August 2020 at 9.00 AM (EET)Insider information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on manufacturing plans for Traumakine, its investigational intravenous (IV)

Change of Adviser

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 27 July 2020 at 9.00 AM (EET) TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company’s Broker. For further information, please contact: Faron Pharmaceuticals Oy Dr Markku Jalkanen, Chief Executive Officer investor.relations@faron.

Faron hosts virtual R&D Day today

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron hosts virtual R&D Day todayCompany announcement, 16 June 2020 at 9.01 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, will today host a virtual R&D Day via webcast to present its R&D strategy and provide insight into Faron’s two clinical stage programmes, Clevegen and Traumakine. The event will take place today at 3.00 p.m. EEST, 1.00 p.m. BST, 8.00 a.m. EDT. Further to the announcement earlier today, no new price sensitive information will

Faron update on pipeline progress ahead of R&D Day

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron provides update on pipeline progress ahead of R&D DayCompany announcement, 16 June 2020 at 9.00 AM (EET) Inside information  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on the progress of its two clinical stage programmes, Clevegen and Traumakine, ahead of the Company’s virtual R&D Day.   Clevegen Clevegen is Faron’s wholly-owned novel precision cancer immunotherapy, targeting Clever-1 positive tumour

Faron receives EUR 2.1 million funding from BF

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron receives €2.1 million funding from Business Finland for Traumakine manufacturing Company announcement, 15 June 2020 at 9.00 AM (EET)Insider information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to initiate a new state of the art process for the manufacturing of interferon (IFN) beta-1a. To support this, Faron has received a €2,100,000 low interest rate loan from Business Finland, the governmental innovation financing

MATINS Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) ·Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual · Patient recruitment for Part II in multiple cohorts progressing well    Company announcement, 01 June 2020 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of

Faron announces R&D Day to be held in June

Faron Pharmaceuticals Oy (“Faron” or the “Company”)Company announcement, 28 May 2020 at 9.00 AM (EET)   TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT. The event will provide an opportunity for the Company’s management team to present its R&D strategy and provide insight into Faron’s two clinical stage programmes. Management will discuss the Company’s wholly-owned novel precision cancer

Faron Pharmaceuticals Oy Harmful association of glucocorticoids in interferon beta-1a treated patients published in Intensive Care Medicine

· Detailed analyses following INTEREST trial conclude glucocorticoids block the upregulation of CD73 in the lung capillaries and inhibit interferon signallingTURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the results of its detailed analyses into the effects of glucocorticoids on intravenous (IV) interferon (IFN) beta-1a activity, which arose following the INTEREST trial in 2018, have been published in Intensive Care Medicine, a world leading journal in the field of critical care. The results

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe